Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1856 results
October 2019
-
Story Discovery
Women in Science: Lauren Abrey
Learn about the career of our Global Medical Affairs Head for Solid Tumors and Rare Diseases.
-
Ad hoc release
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)[1] Novartis plans FDA submission… -
Press release
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
Multiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercializedNovartis to establish… -
Featured News
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
September 2019
-
Story Discovery
Word on the Street: What is cell and gene therapy?
We leave the lab to find out what people know about cell and gene therapy.
-
Press release
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint[1] PALLADIUM is part of Phase III PLATINUM clinical development program,… -
Press release
Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint[1],[2] IRIDIUM is largest study in Phase III PLATINUM clinical… -
Ad hoc release
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs. fulvestrant alone in postmenopausal women (HR=0.724; p=0.00455)[1] Kisqali is the only… -
Featured News
European Patient Innovation Summit recommends increasing the impact of digital technologies
European Patient Innovation Summit publishes a position paper on Digital Health from a Patient Perspective with recommendations on digital health.
-
Story From Our Labs
Seeing through knees in quest to alleviate osteoarthritis
Novartis researchers are peering deep inside knees to see if regenerated cartilage is springy like natural cartilage.
-
Featured News
AveXis data integrity - updates
-
Press release
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate major milestone gainUpdated results from global…